Iron overload in patients with myelodysplastic syndromes.
The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell diseases characterized by ineffective hematopoiesis in one or more cell lines, resulting in insufficient bone marrow function. For most patients with MDS, supportive care by blood transfusions is still the mainstay of treatment. Especially in low-risk patients, anemia represents the major clinical problem, and many of these patients develop transfusional iron overload. This paper reviews the literature on transfusional iron overload in patients with MDS, looking at pathophysiology, evaluation, and treatment of the transfusional iron burden with desferrioxamine and oral chelators.